Posted by Michael Wonder on 11 Dec 2020
Alunbrig scores NICE backing for ALK positive lung cancer
11 December 2020 - Takeda’s Alunbrig (brigatinib) has been recommended by the UK’s NICE for patients with ALK positive advanced non-small cell lung cancer.
Although ALK positive non-small cell lung cancer is rare, it is a particularly resistant disease which mainly affects younger people and non-smokers.
